In our pilot study, we found that FGFR1 knockdown showed the trend of inhibiting tumor growth of sorafenib-resistant cells on the condition of sorafenib and DJ-1 treatment (Figures 7(a)–7(c)). This evidence concerns the gene FGFR1 and neoplasm.